Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Zimmer Biomet Holdings Inc    ZBH

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Zimmer Holdings, Inc. : Zimmer Receives FDA Warning on Certain Hip Implants

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/02/2012 | 12:40am CEST

--Zimmer says FDA inspection of Puerto Rico plant turned up concerns about manufacturing of certain implants

--FDA in letter noted manufacturing, testing issues related to Trilogy Acetabuar System products, company says

--Zimmer says it is notifying customers of manufacturing issue, but hasn't withdrawn any products

(Adds context on metallic spikes in fourth paragraph and a no comment from Zimmer in seventh paragraph.)

 
   By Kristin Jones 
 

Zimmer Holdings Inc. (ZMH) said a U.S. Food and Drug Administration inspection of its plant in Puerto Rico turned up concerns about the manufacturing of certain hip implants.

The orthopedic maker's Zimmer Inc. subsidiary received a warning letter from the FDA dated Sept. 19, the company said in a regulatory filing Monday. In the letter, the FDA noted manufacturing and testing issues related to the company's Trilogy Acetabular System products, which are implanted in hip-replacement surgery.

Specifically, the U.S. drug regulator noted that Zimmer hadn't implemented a testing mechanism to show that its products met design specifications. The company also hadn't validated the effect of certain manufacturing operations on Trilogy products that incorporate metallic spikes.

Spikes are used to connect the hip replacement cup to a patient's bone when cement and screws are deemed insufficient.

The FDA requires that drug and medical-device makers undertake steps to ensure the quality of the design and manufacture of its products, known as process validation.

Zimmer said it is notifying customers of the manufacturing issue, but that it hasn't withdrawn any products. The company also said it previously suspended release of the spiked products, pending validation of the processes cited in the letter, and expects to complete validation in the next few weeks.

A Zimmer spokesman declined to comment further.

Shares gained 11 cents to $67.98 in after-hours trading. Through Monday's close, the stock was up 27% so far this year.

--Joseph Walker contributed to this article.

Write to Kristin Jones at kristin.jones@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ZIMMER BIOMET HOLDINGS INC
07/21 ZIMMER BIOMET HOLDINGS, INC. : Other Events (form 8-K)
07/20 ZIMMER BIOMET : Reports Certain Preliminary Second Quarter 2017 Results
07/17 ZIMMER BIOMET : Judge awards Stryker $248.7M in patent-infringement case
07/11DJZIMMER BIOMET : Announces Leadership Transition
07/11 ZIMMER BIOMET HOLDINGS, INC. (NYSE : ZBH) Files An 8-K Results of Operations and..
07/11 ZIMMER BIOMET HOLDINGS, INC. : Results of Operations and Financial Condition, Ch..
07/11 ZIMMER BIOMET : Reports Certain Preliminary Second Quarter 2017 Results
07/11 ZIMMER BIOMET : Announces Leadership Transition
07/04 ZIMMER BIOMET : Company Admits Paying Bribes to Public Health Care Doctors in Ex..
07/01 ZIMMER BIOMET : introduces X-ray-based patient specific instrument system, X-PSI..
More news
News from SeekingAlpha
07/18 Game Plan For The Week - Cramer's Mad Money (7/17/17)
07/14 Premarket analyst action - healthcare
07/12 Premarket analyst action - healthcare
07/11 Zimmer sees Q2 top line of $1.954B, EPS of ~$2.08; shares down 2% after hours
07/11 Zimmer Biomet chief steps down; shares ease 2% after hours
Financials ($)
Sales 2017 7 863 M
EBIT 2017 2 483 M
Net income 2017 1 204 M
Debt 2017 9 370 M
Yield 2017 0,73%
P/E ratio 2017 24,58
P/E ratio 2018 19,17
EV / Sales 2017 4,52x
EV / Sales 2018 4,23x
Capitalization 26 135 M
Chart ZIMMER BIOMET HOLDINGS INC
Duration : Period :
Zimmer Biomet Holdings Inc Technical Analysis Chart | ZBH | US98956P1021 | 4-Traders
Technical analysis trends ZIMMER BIOMET HOLDINGS INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 136 $
Spread / Average Target 5,2%
EPS Revisions
Managers
NameTitle
Daniel P. Florin Director, Chief Executive & Financial Officer
Larry C. Glasscock Non-Executive Chairman
Adrian Furey Senior VP-Global Operations & Logistics
David J. Kunz VP-Global Quality, Clinical & Regulatory Affairs
Arthur Joseph Higgins Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ZIMMER BIOMET HOLDINGS INC25.59%26 135
MEDTRONIC PLC19.57%115 748
BAXTER INTERNATIONAL41.34%34 072
C R BARD INC43.43%23 334
HOYA CORPORATION18.31%20 410
TERUMO CORP-0.92%14 636